Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AB Sciex Delivers Breakthrough for Therapeutic Biologics with Innovative CESI-MS Solution

Published: Wednesday, March 05, 2014
Last Updated: Wednesday, March 05, 2014
Bookmark and Share
First robust, commercially available ultra-low flow electrospray ionization instrument links CE technology to mass spectrometry for groundbreaking results.

Developing new life-saving drugs and improving the efficacy and quality of existing therapeutic biologics drive the demand for innovation in the biopharmaceutical industry.  To address this need, AB Sciex LLC, today introduced a breakthrough technology solution called CESI-MS. CESI marks a novel combination of capillary electrophoresis (CE) and electrospray ionization (ESI) technologies to create an integrated workflow solution unlike anything else on the market.  With this new solution, biopharmaceutical scientists will be able to more accurately predict efficacy, reduce the time to market for new therapeutics and proactively detect potential issues before they lead to costly product recalls.

The CESI-MS workflow includes the industry's first commercially available ultra low-flow separation and ESI module for biologics, along with a high-performance, high-resolution, accurate mass instrument that is ideal for biopharmaceutical development. The new CESI 8000 System for Biologics Characterization is an innovative, high-performance separation-electrospray ionization system for mass spectrometry (MS).  This new front-end CESI technology from the company's SCIEX Separations business can be integrated with the well-established AB Sciex TripleTOF® 5600+ mass spectrometry system into a seamless solution, for example, to give biopharmaceutical scientists the ability to advance therapeutics discovery, research and development through the life cycle of the product. 

With a single approach that increases efficiency and productivity, the CESI 8000 system provides orthogonal and/or superior results compared to dual-method liquid chromatography / mass spectrometry-based approaches.  From a single digest and run, users of CESI-MS gain the following: (a) Identity and Purity information with 100 percent coverage in a peptide map; (b) Heterogeneity information with ultrasensitive glycopeptide quantitation; and (c) Stability information identifying, deamidation, cyclization and oxidation ‒ all highly important to biopharmaceutical scientists.

"AB SCIEX is partnering with biopharmaceutical companies around the world to advance biologics," said Jeff Chapman, Director of the CE Business within SCIEX Separations, a part of AB Sciex.  "With CESI-MS, we are establishing a new benchmark of improved system performance for routine biologics analysis in a way that allows CESI to be easily integrated into existing workflows in biopharmaceutical laboratories.  This is innovation delivered to help save more lives and address the unmet needs of our customers in biopharma." 

The CESI 8000 system is the first CE-related product launch from AB Sciex.  Expanding its portfolio of separations solutions, AB Sciex obtained the CESI technology through combining the CE business of Beckman Coulter Life Sciences with Eksigent nano and microscale chromatography to form a newly expanded separations business known as SCIEX Separations. 

The new CESI-MS solution is part of AB Sciex's BiologicsFocus Initiative, which is a long-term strategy for AB Sciex to meet the evolving needs of biopharmaceutical scientists by providing innovative technologies and workflow solutions for therapeutic biologics. 

"The new CESI system complements our AB Sciex 'quantitation by design' approach, which puts the power of highly accurate quantitative analysis of large molecules into the hands of biopharma scientists," said Joe Fox, Senior Director of the Pharmaceutical Business at AB Sciex.  "As we work with biopharma companies on addressing new challenges, we see a rising demand for mass spectrometry in biologics that we are uniquely positioned to address.  Our history and experience in this area, which now dates back more than a decade, combined with the exciting addition of the CESI product to the portfolio, will allow us to further our support of these key customers."

CE technology is already well integrated into the workflows of biopharmaceutical companies for the characterization and quality control of therapeutic antibodies, providing fast and efficient separations of intact biologics, automating SDS-Gel, isoelectric focusing and glycan analysis. The technical benefit of the CESI innovation delivered to biopharmaceutical laboratories is an improvement in biophysicochemical characterization to guide the development of biologics-based therapeutics. Specifically, CESI-MS serves to improve ionization efficiency and reduce ion suppression. AB Sciex is delivering this advancement as a robust solution - without requiring specialized expertise in CE or MS.

The CESI 8000, which is manufactured by Beckman Coulter, is an expansion to the CE portfolio within the newly expanded SCIEX Separations.  This portfolio also includes the PA 800 plus™pharmaceutical analysis system, the GeXP™ genetic analyzer and the P/ACE™ MDQ capillary electrophoresis system.Switching between LC-MS and CESI-MS has also been made simple, which will help facilitate adoption of CESI-MS technology.  The data that are generated on the CESI-based workflow are complementary to data from LC-MS/MS solutions.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Collaboration to Develop Cannabis Testing Standards
SCIEX workflow solution enables cannabis labs to ensure product safety with robust, cost-effective analytical methods to facilitate routine testing.
Tuesday, September 13, 2016
SCIEX Works with the Francis Crick Institute and the University of Cambridge
New proteomic study to develop advanced resource for precision medicine research by using Microflow SWATH® Acquisition for HT industrialized proteomics.
Wednesday, June 29, 2016
SCIEX, QPS Holdings Collaborate
Agreement aims to advance the hybrid LBA-LCMS workflow for biologics quantification.
Wednesday, April 06, 2016
SCIEX, Children's Medical Research Institute Collaborate
SCIEX industrialized proteomics solutions, using SWATH® Acquisition-based workflows and powered by the OneOmics™ Project, will enable large scale proteome studies to advance cancer research.
Thursday, February 11, 2016
SCIEX, A*STAR’s BTI Launch Collaboration
Agreement aims to boost innovation of protein drugs that target new diseases and are safer for patients.
Wednesday, January 27, 2016
SCIEX, Pressure BioSciences Partner
SCIEX and Pressure BioSciences to offer complete solution for next-generation proteomics, to increase the reproducibility and depth of proteomic analysis.
Wednesday, January 13, 2016
SCIEX, University of Manchester Partner
SWATH® Acquisition-based next-generation proteomics technology promises to make industrial proteomics a reality.
Thursday, October 29, 2015
SCIEX Partners with the Paulovich Lab at Fred Hutchinson Cancer Research Center
Collaboration targets research reproducibility crisis with highly validated multiplex quantitation assays.
Wednesday, September 23, 2015
SCIEX and New Objective Announce Partnership
New nanospray sources to offer maximum sensitivity and robustness for NanoLC-MS.
Tuesday, June 02, 2015
SCIEX and New Objective Partner
Partnership will provide advanced nanospray ionization technologies for next-generation proteomics.
Tuesday, May 26, 2015
SCIEX and Hepregen Announce Co-Marketing Agreement
Alliance establishes SCIEX and Hepregen as a one-stop solution provider for drug metabolism investigators.
Friday, May 22, 2015
SCIEX and Mass Consortium Corporation Announce Exclusive Reseller Agreement
SCIEX to provide customers with XCMSplus software solution for simplified and accelerated metabolomics workflows.
Tuesday, March 31, 2015
SCIEX and Labor Berlin Collaboration to Advance Forensic Testing
Collaboration for the development of a hybrid Quadrupole Time-of-Flight (TOF) MS/MS reference library.
Thursday, March 05, 2015
New Capabilities for Bioanalysis Studies at the International Pharmaceutical Research Center
AB SCIEX Triple Quad™ 6500 LC/MS/MS systems enable new levels of sensitivity for clinical trials of inhaled drugs.
Wednesday, February 11, 2015
Improved Accuracy of Pesticide Detection in Food
European Reference Laboratory improves accuracy of pesticide detection in food with AB SCIEX mass spectrometry instrumentation.
Wednesday, February 04, 2015
Scientific News
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
Hunting the Missing Link Between Genetics and the Environment
The International Phenome Centre Network (IPCN) works to transform healthcare through phenomics - the dynamic interactions between our genes and our environment.
Cocaine Test Could Lead to Rapid, Low Cost Roadside Testing
Scientists develop urine and oral fluid diagnostic test for cocaine, utilising a compact mass spectrometer.
The Benefits of a Mediterranean-style Diet
A Western-style diet, with more omega-6 fatty acids than the Mediterranean, dysregulates lipid signaling in aged mice and promotes inflammation.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Rapid Identification of Illicit Designer Drugs
New technique can identify commonly used illicit compounds in as little as 15 seconds.
Enhancing On-line Biological Sample Processing
New techniques are required to meet emerging demands on biopharmaceutical analysis.
Early Warning System for Colorectal Cancer
Potential new diagnostic tool identified for the second most common cancer in the world.
Scientists Develop a Novel Method to Benchmark and Improve the Performance of Protein Measurement Techniques
A wide range of laboratories around the world are benefiting from this work, which enables researchers to analyze or compare the results of quantitative proteomics assays in a standardized way.
Amyloid Study Pinpoints Protein Culprits
A five-year trial at a Brisbane Hospital has increased the accuracy of diagnosing patients with amyloidosis, a group of rare and incurable diseases caused by abnormal protein deposits in tissues and organs.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!